|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FUNDC2 |
Gene summary for FUNDC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FUNDC2 | Gene ID | 65991 |
| Gene name | FUN14 domain containing 2 | |
| Gene Alias | DC44 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000422 | UniProtAcc | Q9BWH2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65991 | FUNDC2 | C04 | Human | Oral cavity | OSCC | 1.31e-28 | 1.94e+00 | 0.2633 |
| 65991 | FUNDC2 | C21 | Human | Oral cavity | OSCC | 1.50e-59 | 2.27e+00 | 0.2678 |
| 65991 | FUNDC2 | C30 | Human | Oral cavity | OSCC | 4.57e-40 | 2.10e+00 | 0.3055 |
| 65991 | FUNDC2 | C38 | Human | Oral cavity | OSCC | 4.75e-07 | 1.09e+00 | 0.172 |
| 65991 | FUNDC2 | C43 | Human | Oral cavity | OSCC | 1.38e-49 | 1.07e+00 | 0.1704 |
| 65991 | FUNDC2 | C46 | Human | Oral cavity | OSCC | 2.21e-18 | 6.56e-01 | 0.1673 |
| 65991 | FUNDC2 | C51 | Human | Oral cavity | OSCC | 4.11e-17 | 1.22e+00 | 0.2674 |
| 65991 | FUNDC2 | C57 | Human | Oral cavity | OSCC | 5.27e-05 | 5.14e-01 | 0.1679 |
| 65991 | FUNDC2 | C06 | Human | Oral cavity | OSCC | 8.25e-13 | 1.85e+00 | 0.2699 |
| 65991 | FUNDC2 | C07 | Human | Oral cavity | OSCC | 3.81e-06 | 1.73e+00 | 0.2491 |
| 65991 | FUNDC2 | C08 | Human | Oral cavity | OSCC | 1.18e-45 | 1.05e+00 | 0.1919 |
| 65991 | FUNDC2 | C09 | Human | Oral cavity | OSCC | 5.20e-08 | 3.53e-01 | 0.1431 |
| 65991 | FUNDC2 | LN22 | Human | Oral cavity | OSCC | 4.05e-06 | 9.63e-01 | 0.1733 |
| 65991 | FUNDC2 | LN38 | Human | Oral cavity | OSCC | 8.76e-05 | 1.08e+00 | 0.168 |
| 65991 | FUNDC2 | LN46 | Human | Oral cavity | OSCC | 3.97e-03 | 5.34e-01 | 0.1666 |
| 65991 | FUNDC2 | LP15 | Human | Oral cavity | LP | 1.88e-02 | 9.73e-01 | 0.2174 |
| 65991 | FUNDC2 | LP17 | Human | Oral cavity | LP | 3.92e-06 | 9.87e-01 | 0.2349 |
| 65991 | FUNDC2 | SYSMH1 | Human | Oral cavity | OSCC | 2.51e-09 | 2.91e-01 | 0.1127 |
| 65991 | FUNDC2 | SYSMH2 | Human | Oral cavity | OSCC | 1.95e-09 | 5.16e-01 | 0.2326 |
| 65991 | FUNDC2 | SYSMH3 | Human | Oral cavity | OSCC | 4.35e-19 | 7.89e-01 | 0.2442 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:19030089 | Esophagus | HGIN | organelle disassembly | 36/2587 | 114/18723 | 8.60e-07 | 3.58e-05 | 36 |
| GO:000042216 | Esophagus | HGIN | autophagy of mitochondrion | 25/2587 | 81/18723 | 5.95e-05 | 1.38e-03 | 25 |
| GO:006172616 | Esophagus | HGIN | mitochondrion disassembly | 25/2587 | 81/18723 | 5.95e-05 | 1.38e-03 | 25 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
| GO:000042217 | Esophagus | ESCC | autophagy of mitochondrion | 63/8552 | 81/18723 | 3.41e-09 | 7.24e-08 | 63 |
| GO:006172617 | Esophagus | ESCC | mitochondrion disassembly | 63/8552 | 81/18723 | 3.41e-09 | 7.24e-08 | 63 |
| GO:00224117 | Liver | Cirrhotic | cellular component disassembly | 182/4634 | 443/18723 | 1.59e-14 | 1.54e-12 | 182 |
| GO:19030084 | Liver | Cirrhotic | organelle disassembly | 59/4634 | 114/18723 | 4.82e-10 | 2.27e-08 | 59 |
| GO:00004225 | Liver | Cirrhotic | autophagy of mitochondrion | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
| GO:00617265 | Liver | Cirrhotic | mitochondrion disassembly | 43/4634 | 81/18723 | 4.02e-08 | 1.31e-06 | 43 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:190300811 | Liver | HCC | organelle disassembly | 89/7958 | 114/18723 | 8.68e-15 | 5.73e-13 | 89 |
| GO:000042211 | Liver | HCC | autophagy of mitochondrion | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
| GO:006172611 | Liver | HCC | mitochondrion disassembly | 64/7958 | 81/18723 | 1.96e-11 | 7.72e-10 | 64 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:19030088 | Oral cavity | OSCC | organelle disassembly | 85/7305 | 114/18723 | 1.15e-14 | 6.93e-13 | 85 |
| GO:000042210 | Oral cavity | OSCC | autophagy of mitochondrion | 59/7305 | 81/18723 | 6.40e-10 | 1.63e-08 | 59 |
| GO:006172610 | Oral cavity | OSCC | mitochondrion disassembly | 59/7305 | 81/18723 | 6.40e-10 | 1.63e-08 | 59 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FUNDC2 | SNV | Missense_Mutation | rs782780466 | c.170N>T | p.Ala57Val | p.A57V | Q9BWH2 | protein_coding | deleterious(0.04) | benign(0.03) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| FUNDC2 | insertion | Frame_Shift_Ins | novel | c.328_329insGAAAATCATTCAGTTGCTTGGTGAGCCTCAGTAAACACCAC | p.Thr110ArgfsTer44 | p.T110Rfs*44 | Q9BWH2 | protein_coding | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| FUNDC2 | insertion | Frame_Shift_Ins | novel | c.534_535insT | p.Gly181ArgfsTer56 | p.G181Rfs*56 | Q9BWH2 | protein_coding | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD | ||
| FUNDC2 | SNV | Missense_Mutation | c.387N>C | p.Lys129Asn | p.K129N | Q9BWH2 | protein_coding | tolerated(0.07) | possibly_damaging(0.869) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FUNDC2 | SNV | Missense_Mutation | c.263N>G | p.Phe88Cys | p.F88C | Q9BWH2 | protein_coding | deleterious(0.02) | possibly_damaging(0.518) | TCGA-AA-3831-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FUNDC2 | SNV | Missense_Mutation | c.86G>A | p.Arg29His | p.R29H | Q9BWH2 | protein_coding | deleterious_low_confidence(0.04) | benign(0.277) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FUNDC2 | SNV | Missense_Mutation | c.533G>A | p.Gly178Glu | p.G178E | Q9BWH2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FUNDC2 | SNV | Missense_Mutation | novel | c.432G>T | p.Glu144Asp | p.E144D | Q9BWH2 | protein_coding | tolerated(0.05) | benign(0.111) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FUNDC2 | SNV | Missense_Mutation | c.500C>T | p.Ser167Leu | p.S167L | Q9BWH2 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FUNDC2 | SNV | Missense_Mutation | novel | c.57C>A | p.His19Gln | p.H19Q | Q9BWH2 | protein_coding | tolerated_low_confidence(0.32) | benign(0.003) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |